MBX BIOSCIENCES INC. - COMMON STOCK

MBX Biosciences Announces Additions to Leadership Team

05 3 2025 08:00:00 提供 Nasdaq GlobeNewswire

MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism

03 3 2025 08:00:00 提供 Nasdaq GlobeNewswire

MBX Biosciences to Participate in March Investor Conferences

18 2 2025 08:00:00 提供 Nasdaq GlobeNewswire

MBX Biosciences to Participate in Upcoming February Investor Conferences

23 1 2025 08:00:00 提供 Nasdaq GlobeNewswire

MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia

07 1 2025 07:00:00 提供 Nasdaq GlobeNewswire

MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference

18 12 2024 08:00:00 提供 Nasdaq GlobeNewswire

MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism

02 12 2024 08:00:00 提供 Nasdaq GlobeNewswire

MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

18 11 2024 08:00:00 提供 Nasdaq GlobeNewswire

MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update

07 11 2024 08:00:01 提供 Nasdaq GlobeNewswire

MBX Biosciences to Participate in Upcoming November Investor Conferences

28 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting

30 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

16 9 2024 16:05:00 提供 Nasdaq GlobeNewswire